Myra M. Mizokami - Concepedia

Author

Myra M. Mizokami

Also Known As

M M Mizokami, M Mizokami, M. M. Mizokami, Myra M. Mizokami, Myra Mizokami

Publications

263

Citations

H-Index

Concepts

All Affiliations

Myra M. Mizokami is an author at University of Southern California specializing in immunotherapy, tumor microenvironment, and immunology.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	105
2	Immunology	2	2	105
3	Pathology	1	1	61
4	Pharmacology	1	1	44
5	Clinical Chemistry	1	1	44

Myra M. Mizokami

Publications

261

Citations

H-Index

Page 1

	Year	Citations
A New Chemically Modified Chimeric TNT-3 Monoclonal Antibody Directed Against DNA for the Radioimmunotherapy of Solid Tumors Jason L. Hornick, Jahangir Sharifi, Leslie A. Khawli, Cancer Biotherapy and Radiopharmaceuticals Solid TumorsImmunologyPathologyImmunotherapyTumor Biology	1998	61
Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability Alan L. Epstein, Myra M. Mizokami, Jun Li, JNCI Journal of the National Cancer Institute	2003	45
Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin Leslie A. Khawli, Myra M. Mizokami, Jahangir Sharifi, Cancer Biotherapy and Radiopharmaceuticals ImmunologyChemical ModificationImmunotherapyTumor BiologyRadiopharmaceutical Therapy	2002	44
Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Peisheng Hu, Myra M. Mizokami, Gina Ruoff, Blood	2003	42
Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. Jason L. Hornick, Jahangir Sharifi, Leslie A. Khawli, PubMed	2000	39
Chimeric TNT-3 Antibody/Murine Interferon- <i>γ</i> Fusion Protein for the Immunotherapy of Solid Malignancies Myra M. Mizokami, Peisheng Hu, Leslie A. Khawli, Hybridoma and Hybridomics	2003	30

Page 1